OMICS International Organises 3000+ Global Conferenceseries Events Every Year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open access journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
For more Conferences visit www.conferenceseries.com

Back

Owen A. O’Connor

Owen A. O’Connor

Center for Lymphoid Malignancies
Columbia University Medical Center

Professor

Biography

Owen A. O’Connor, M.D., Ph.D., Associate Professor of Medicine, is the Director of the Lymphoid Development and Malignancy Program in the Herbert Irving Comprehensive Cancer Center at Columbia University, and Chief of the Lymphoma Service in the College of Physicians and Surgeons at New York- Presbyterian Hospital/Columbia University Medical Center. Dr. O’Connor received his Ph.D. from the New York University School of Medicine in Biochemical Toxicology and Chemical Carcinogenesis, and his M.D. from the University of Medicine and Dentistry of New Jersey. He then went on to complete a medical internship and residency at The New York Hospital-Cornell University Medical Center. Following his medical residency, he did a fellowship in Medical Oncology at the Memorial Sloan Kettering Cancer Center, where he was Chief Fellow from 1997-1998, and a Fellowship in Clinical Pharmacology at the New York Hospital-Cornell University Medical Center. Dr. O’Connor maintains a laboratory program focused on the discovery of novel small molecules for the treatment of non-Hodgkin\\\\\\\\\\\\\\\'s lymphoma and Hodgkin\\\\\\\\\\\\\\\'s disease using unique animal models of lymphoma and high-throughput screening approaches. Clinically, he is focused on the conduct of Phase I and II clinical trials, with an emphasis on pharmacokinetic and pharmacodynamic studies. He has a particular interest in the development of proteasome inhibitors, histone deacetylase inhibitors and Bcl-2 targeted drugs for the treatment of lymphoproliferative malignancies. To date, his efforts in conducting early phase clinical trials with bortezomib (Velcade) and SAHA (Vorinostat) have led to recent FDA approvals of these drugs for the treatment of mantle cell and cutaneous T-cell lymphoma. Dr. O’Connor is a member of several professional societies, including the American Association for Cancer Research, the American Society for Clinical Oncology, the American Society of Clinical Pharmacology and Therapeutics, and the American Society for Hematology. He has published nearly 100 articles in numerous journals, including Proceedings of the National Academy of Science, Journal of Clinical Oncology, British Journal of Hematology, Leukemia and Lymphoma, Clinical Cancer Research, Environmental Science and Technology and Environmental Toxicology and Chemistry. Dr. O’Connor is the recipient of several honors and awards, including the Scholar in Clinical Research Award from the Leukemia and Lymphoma Society, a Merit Award from the American Society for Clinical Oncology, and the William Guy Forbeck Scholar Award.

Research

Acute Lymphocytic Leukemia, Hematologic Abnormality, Hematologic Malignancy, Hodgkin\\\\\\\'s disease, Leukemia, Lymphoma, Myeloma, Multiple Myeloma, Non Hodgkin\\\\\\\'s Lymphoma